153 related articles for article (PubMed ID: 15331411)
1. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
Van Valckenborgh E; Croucher PI; De Raeve H; Carron C; De Leenheer E; Blacher S; Devy L; Noël A; De Bruyne E; Asosingh K; Van Riet I; Van Camp B; Vanderkerken K
Am J Pathol; 2004 Sep; 165(3):869-78. PubMed ID: 15331411
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
5. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Biochem Biophys Res Commun; 2004 Apr; 316(3):859-66. PubMed ID: 15033480
[TBL] [Abstract][Full Text] [Related]
6. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
[TBL] [Abstract][Full Text] [Related]
7. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; King P; Vande Broek I; De Raeve H; Van Camp B; Croucher P; Vanderkerken K
Leukemia; 2009 Oct; 23(10):1894-903. PubMed ID: 19494837
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; Vande Broek I; De Raeve H; Coulton L; Van Camp B; Croucher P; Vanderkerken K
Cancer Res; 2009 Jul; 69(13):5307-11. PubMed ID: 19531653
[TBL] [Abstract][Full Text] [Related]
9. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
10. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
12. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
13. Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions.
Wahlgren J; Maisi P; Sorsa T; Sutinen M; Tervahartiala T; Pirilä E; Teronen O; Hietanen J; Tjäderhane L; Salo T
J Pathol; 2001 Jun; 194(2):217-24. PubMed ID: 11400151
[TBL] [Abstract][Full Text] [Related]
14. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
Menu E; Jernberg-Wiklund H; De Raeve H; De Leenheer E; Coulton L; Gallagher O; Van Valckenborgh E; Larsson O; Axelson M; Nilsson K; Van Camp B; Croucher P; Vanderkerken K
Int J Cancer; 2007 Oct; 121(8):1857-61. PubMed ID: 17546599
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis.
Blavier L; Lazaryev A; Dorey F; Shackleford GM; DeClerck YA
Cancer Res; 2006 Mar; 66(5):2691-9. PubMed ID: 16510589
[TBL] [Abstract][Full Text] [Related]
16. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
[TBL] [Abstract][Full Text] [Related]
17. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.
Winding B; NicAmhlaoibh R; Misander H; Høegh-Andersen P; Andersen TL; Holst-Hansen C; Heegaard AM; Foged NT; Brünner N; Delaissé JM
Clin Cancer Res; 2002 Jun; 8(6):1932-9. PubMed ID: 12060638
[TBL] [Abstract][Full Text] [Related]
18. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.
Vanderkerken K; De Greef C; Asosingh K; Arteta B; De Veerman M; Vande Broek I; Van Riet I; Kobayashi M; Smedsrod B; Van Camp B
Br J Cancer; 2000 Feb; 82(4):953-9. PubMed ID: 10732771
[TBL] [Abstract][Full Text] [Related]
19. Antimyeloma effects of resveratrol through inhibition of angiogenesis.
Hu Y; Sun CY; Huang J; Hong L; Zhang L; Chu ZB
Chin Med J (Engl); 2007 Oct; 120(19):1672-7. PubMed ID: 17935668
[TBL] [Abstract][Full Text] [Related]
20. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model.
Van Valckenborgh E; Mincher D; Di Salvo A; Van Riet I; Young L; Van Camp B; Vanderkerken K
Leukemia; 2005 Sep; 19(9):1628-33. PubMed ID: 16015389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
